Name:
Venolife. Release formGel for external use. Dosage 40 g. Pack quantity: 1 pc. ProducerAkrikhin. INN Heparin sodium + dexpanthenol + troxerutin. FTGVenotonic and venoprotective agent. Composition 1 g of gel contains: active substances: troxerutin – 0.02 g, sodium heparin – 0.0025 g (300 IU), dexpanthenol – 0.05 g; excipients: phenylethanol 0.01 g, propylene glycol 0.1 g, carbomer 940 or 980 0.008 g, trometamol 0.004 g, purified water up to 1 g.
Description:
Transparent or almost transparent light yellow gel with a specific odor. Pharmacotherapeutic group Heparins or heparinoids for external use. ATX code: C05BA53 Pharmacological propertiesPharmacodynamics Venolife® gel is a combined preparation for external use, the pharmacological properties of which are determined by the action of its constituent substances. Heparin – a direct anticoagulant, a natural anticoagulant factor of the body – has an anti-inflammatory effect, promotes the regeneration of connective tissue by inhibiting the activity of hyaluronidase; prevents thrombosis, activates the fibrinolytic properties of blood; improves local blood flow. Dexpanthenol – provitamin B5 – in the skin turns into pantothenic acid, which is part of coenzyme A, which plays an important role in the processes of acetylation and oxidation; improving metabolic processes, dexpanthenol promotes the regeneration of damaged tissues; improves heparin absorption. Troxerutin is an angioprotective agent; has P-vitamin activity (reduces vascular tissue permeability and fragility of capillaries), contributes to the normalization of microcirculation and tissue trophism, reduces congestion in veins and paravenous tissues; has anti-exudative and anti-inflammatory effect. Pharmacokinetics When applied topically, the active substances are quickly absorbed by the skin. Heparin accumulates in the upper layers and actively binds to skin proteins, dexpanthenol penetrates into all layers of the skin and turns into pantothenic acid, after 30 minutes troxerutin is found in the dermis, and after 2-5 hours in the subcutaneous fatty tissue. Indications for use As part of complex therapy: edematous-pain syndrome and microcirculatory-trophic disorders caused by venous insufficiency of the lower extremities (varicose veins, chronic thrombophlebitis, post-thrombophlebitic syndrome, chronic lymphostasis); soft tissue injuries (hematomas, dislocations, sprains); to accelerate granulation and epithelialization of trophic ulcers in the regeneration phase (in the absence of pronounced exudation). Contraindications in the case of heparin-induced thrombocytopenia type II (HIT type II, mediated by immunity) in history; hypersensitivity to the components of the drug; open infected wounds or wounds with profuse exudation at the site of application; children’s age up to 18 years. Use in children There are no data on the use of troxerutin preparations in children. Use during pregnancy and lactation There are no data on the use of troxerutin preparations during pregnancy and lactation. Application is possible only after consulting a doctor, taking into account the ratio of the possible risk to the fetus / child and the benefit to the woman. Dosage and administration Externally. Apply a thin layer to the affected area 2-3 times a day, evenly distributing over the skin surface with light rubbing movements until completely absorbed. The course of treatment is 2-3 weeks. The need for further treatment is determined by the attending physician, based on the severity of the pathological process and the results of clinical tests. With a recurrence of the disease, the course of treatment can be carried out 2-3 times a year. In case of trophic ulcers with weak exudation, before using the drug, the wound surface is cleaned of exudate and necrotic tissues, if necessary, washed with a solution of hydrogen peroxide 3%, nitrofural 1:5000 or chlorhexidine bigluconate 0.05% and dried. The gel is applied in a uniform thin layer so that the entire affected surface is covered with the drug, and a sterile gauze bandage is applied. Dressings are changed once a day. With an open method of treatment, the drug is applied 1-2 times a day. The duration of treatment is determined by the dynamics of epithelialization. Special categories of patients Elderly: dose adjustment is not required. Patients with impaired liver function: dose adjustment is not required. Patients with impaired renal function: dose adjustment is not required. Side effects Allergic reactions to heparin after applying the drug to the skin are very rare. However, in some cases, hypersensitivity reactions may occur, such as redness of the skin and itching, which quickly disappear after discontinuation of the drug. Not known: The incidence of heparin-induced antibody-mediated thrombocytopenia type II (platelet count < 100,000/mcL or abrupt decrease in platelet count to < 50% of baseline with arterial and venous thrombosis and embolism) has not been studied with topical heparin. However, since penetration into healthy skin has been described, this risk cannot be ruled out. In this regard, it is recommended to exercise increased caution (see section "Precautions"). With parenteral heparin in patients without pre-existing hypersensitivity to heparin, a decrease in platelet count can usually occur 6 to 14 days after the start of treatment. In patients with hypersensitivity to heparin, thrombocytopenia may develop within a few hours. Overdose Overdose is unlikely due to the low systemic absorption of the gel components. Precautions If there are signs of bleeding, the possibility of using Venolife® should be carefully considered. Venolife® should not be used for bleeding, applied to open wound surfaces, weeping eczema or mucous membranes, as well as to infected areas in the presence of purulent processes. Penetration of heparin into healthy skin has been described in the case of topical application, therefore, if thromboembolic complications are suspected, a platelet count should be performed to differentially diagnose type II heparin-induced thrombocytopenia. Thus, regular checks of platelet counts in patients with a history of thromboembolic complications are necessary with each use of heparin (before starting heparin, on the first day after the start of use, and then regularly every 3-4 days during treatment until its end). Patients suffering from varicose veins of the lower extremities and venous insufficiency should strictly follow the additional medical measures prescribed by the doctor, such as wearing compression medical stockings (knee socks, stockings), compresses, a cool shower on the area of the lower extremities, etc. within 2 weeks of therapy, worsening of the course of the disease or the appearance of new symptoms, it is recommended to consult a doctor. Special instructions Venolife® is not intended for use in ophthalmology, for intravaginal and rectal administration. The ability to influence the reaction rate when driving vehicles and other mechanisms The drug does not affect the ability to drive a car or work with mechanisms. Interaction with other drugs Use with caution while taking oral anticoagulants due to a possible increase in the effect. Interactions of the drug with other drugs have not been identified. Release formGel for external use. 40 g in an aluminum tube. Each tube, along with instructions for use, is placed in a cardboard box. Storage conditionsAt temperatures from 15 to 25 °C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiration date. Terms of dispensing from pharmaciesWithout a prescription. Buy Venolife gel 40g №1 Price for Venolife gel 40g №1 Instructions for use for Venolife gel 40g №1
Venolife gel 40g №1
$28.00
INN | OTHER |
---|---|
The code | 35 064 |
Barcode | 4 601 969 005 134 |
Dosage | 40g |
Active substance | Troxerutin, dexpanthenol, sodium heparin |
Manufacturer | HFC Akrikhin AO, Russia |
Importer | Foreign unitary trade and manufacturing enterprise "Belinvestfarma", Minsk, Leshchinskogo st., 8/4-2; Limited Liability Company "Farmiko", Minsk district, Senitsky s / s, Kolyadichi village, Lazurnaya st., 9; LLC "Iskamed", Republic of Belarus, 220036, Minsk, K. Liebknekhta st., 70, room 6 |
Be the first to review “Venolife gel 40g №1” Cancel reply
Related products
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Reviews
There are no reviews yet.